bicalutamide + letrozole

Bicalutamide + letrozole is a combination of two oral small molecule drugs, each with distinct mechanisms of action targeting hormone pathways. Bicalutamide is a nonsteroidal antiandrogen that blocks the androgen receptor, inhibiting the effects of testosterone and other androgens, primarily used in prostate cancer therapy[1][3][6]. Letrozole is an aromatase inhibitor that suppresses estrogen synthesis by inhibiting the aromatase enzyme, commonly used in hormone-sensitive breast cancer treatment[7][9]. The combination may be explored for conditions where dual suppression of androgen and estrogen signaling is desired, such as certain cancers or rare endocrine disorders. This combination does not have a unique brand name or fixed-dose formulation; it refers to concurrent use of both agents.